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ABSTRACT 
Background and Aims 
Diagnosis and surveillance of Barrett’s esophagus (BE) and eosinophilic esophagitis 
(EoE) have become emerging public health issues. Cytosponge® is a novel, 
minimally invasive esophageal cell collection device. We aimed to assess the data on 
safety and acceptability of this device. 
Methods 
We performed a patient-level review of 5 prospective trials assessing Cytosponge® 
performance in patients with reflux disease, BE and EoE in primary and secondary 
care. Acceptability of Cytosponge® and subsequent endoscopy were recorded with 
visual analogue scale (VAS), wherein 0 and 10 denoted lowest and highest 
acceptability. Median VAS scores were compared using a Mann-Whitney test. The 
number of attempts, failures in swallowing the device and occurrence of adverse 
events were analyzed. Risk factors for failure in swallowing were analyzed using a 
multivariate regression model. 
Results 
In total 2,672 Cytosponge® procedures were performed in 2,418 individuals between 
2008 and 2017. There were two adverse events related to the device: a minor 
pharyngeal bleed and one case of detachment (<1:2,000). The median acceptability 
score for the Cytosponge® was 6.0 (IQR 5.0-8.0), which was higher than endoscopy 
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without sedation (median 5.0, IQR 3.0-7.0; p<0.001) and lower than endoscopy with 
sedation (median 8.0, IQR 5.0-9.0; p<0.001). Nearly all patients (91.1%) successfully 
swallowed the Cytosponge® and most (90.1%) were achieved with the first swallow 
attempt. Failure to swallow the device was more likely to occur in secondary care 
(OR= 5.13, 95%CI 1.48-17.79, P<0.01). 
Conslusions 
The Cytosponge® test is a safe procedure with good acceptability ratings in a variety 
of health care settings. 
Key words 















Two chronic esophageal diseases - Barrett’s esophagus (BE) and eosinophilic 
esophagitis (EoE) - have become emerging issues in the public health over the last 
several decades1,2,3.  
BE develops on the background of long-standing gastro-esophageal reflux 
disease (GERD) and is defined as a metaplastic change in the esophageal lining, 
from a squamous-type epithelium to a specialized columnar epithelium. The 
estimated population prevalence of BE is 1- 2%4. BE is a major risk factor for 
esophageal adenocarcinoma (EAC) - a cancer with rapidly increasing incidence in 
the Western world5. Patients with chronic GERD and other risk factors (male sex, age 
of ≥ 50 years, white race, family history of BE or EAC) may be offered endoscopic 
screening for the presence of BE6, however most BE cases remain undiagnosed. 
Patients with the benefit of a BE diagnosis undergo endoscopic surveillance with the 
aim to identify neoplastic changes within BE segment at the earliest possible 
stage7,8,9. Such patients are candidates for endoscopic treatment with either 
endoscopic mucosal resection (EMR) or radiofrequency ablation (RFA)10,11 with 
excellent survival results for intra-mucosal disease12.  
EoE, on the other hand, is a relatively newly defined immune-mediated 
disease characterized by predominant eosinophilic inflammation of the esophagus (a 
peak count of ≥ 15 eosinophil per high-power field of biopsy tissue)13. EoE is seen 
predominantly in younger men, however it affects all age groups and both sexes14,15. 
It is one of the most common condition in adult patients leading to food bolus 
impaction. As with BE, most cases of EoE are undiagnosed, and its incidence rate is 
reaching up to 12.8 /100,000 / year in some regions of the US16. The aim of 
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diagnosis and treatment is to control the symptoms, resolve esophageal eosinophilia, 
and reduce complications.  
Although the nature of these two entities is highly disparate, both require long-
term, endoscopic monitoring and repeated collection of mucosal samples to optimize 
and monitor the treatment. To perform systematic screening and surveillance for 
these conditions would constitute a huge burden on health care systems. A survey 
study analyzing trends in endoscopic volume in the US showed that there was a 54% 
increase in upper GI endoscopy between 2000 and 2009, with an estimated number 
of 6.9 million of these procedures performed in 200917. The rising incidence of BE 
and EoE may have contributed to these numbers. Patients with EoE alone have an 
estimated annual health-care cost of as much as $1.4 billion in the US18. 
While diagnostic esophagogastroduodenoscopy (EGD) is considered to be a 
safe procedure, it is not devoid of complications. The overall mortality rates for EGD 
are ranging from none to 1 in 2,000 in various studies19. Perforation, a potentially life-
threatening complication, is reported to occur from 1 in every 2,500 to 1 in every 
11,000 procedures20,21. Moreover, many of the EGDs in the US and Europe are 
performed under sedation, exposing patients to additional risks. These include 
cardiopulmonary complications, which account for as much as 60% of endoscopy 
adverse events and an incidence ranging between 1 in 170 and 1 in 10,00022. 
Therefore, new, less invasive methods of esophageal mucosal sampling are 
being investigated. Cytosponge® is a novel, minimally invasive cell collection device 
that consists of a 30-mm polyurethane sponge, contained within a capsule attached 
to a string. When withdrawn, the device collects esophageal cells for analysis (Figure 
1A). The procedure requires minimal training and can be safely administered by a 
nurse in a primary care setting. Cytosponge® has already been successfully used in 
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several studies to identify BE and EoE23,24,25. The cells retrieved from the sponge are 
spun down and embedded to produce a pseudo-biopsy suitable for routine laboratory 
analysis (Figure 1B-D). To aid the identification of BE, the histopathological analysis 
is coupled with a diagnostic biomarker, Trefoil Factor-3 (TFF-3); Figure 1C. Of note, 
the utility of the Cytosponge® goes beyond the confines of BE and EoE diagnosis 
since a range of pathologies affecting the esophagus and proximal stomach, such as 
esophageal candidiasis, esophageal ulcers, H.pylori infection, intestinal metaplasia at 
the cardia and viral esophagitis can also be diagnosed26.  
The aim of this study was to combine data from 5 large trials on Cytosponge® 
performed in patients with chronic GERD, BE and EoE in 3 different countries (UK, 
USA and Australia) to assess the overall safety and acceptability of this test. 
METHODS 
Study design and study participants 
This was a retrospective, patient-level technical review of prospectively 
collected data. Studies included in the analyses were the Barrett’s ESophagus Trial 1 
(BEST1)24, BEST225, BEST-Australia, the ongoing BEST2-RFA study 
(ClinicalTrials.gov number NCT02106910) and Cytosponge® Eosinophilic Esophagitis 
study (EoE Study, NCT02114606)23. Principal investigators of each trial shared the 
original trial databases. All studies were conducted with the use of Cytosponge® 
approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). 
Briefly, the setting and patients’ eligibility criteria of each study were as 
follows: 
• BEST1: individuals with chronic GERD managed in primary care with long-term 
PPI (>3 months).  
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• BEST2: patients with previously diagnosed BE (cases) and patients with GERD 
without BE (control group) referred to the secondary care unit for endoscopy. 
• BEST-Australia: patients with chronic GERD symptoms referred for endoscopy in 
a secondary care unit.  
• BEST2-RFA: patients with BE with low-grade dysplasia (LGD) or high-grade 
dysplasia (HGD), who received radiofrequency ablation (RFA) or are under 
surveillance following ablative treatment.  
• EoE study: patients with EoE referred for the secondary care unit to undergo 
clinically indicated endoscopy.  
Exclusion criteria were generally consistent between studies and included 
bleeding disorders, known cirrhosis +/- varices, history of esophageal surgery, 
dysphagia and esophageal stricture. An overview of study characteristics is 
presented in Table 1.  
Cytosponge ® Procedure  
The Cytosponge® was administered in a similar fashion in each trial by trained 
research nurses. After swallowing the device in sitting position, the capsule coating 
disintegrates within 5 minutes upon reaching the stomach, revealing a 3-cm diameter 
spherical mesh that is withdrawn by pulling the string. Following its retrieval, the 
string is cut, the Cytosponge® is then immersed in SurePath Preservative Fluid 
(TriPath Imaging, Burlington, North Carolina, USA) and kept at 4oC until transported 
to the laboratory for processing. Hematoxilin Eosin (H&E) staining and 
immunohistochemistry for TFF-3 is then performed on paraffin-embedded 
Cytosponge® specimens by adhering to standard H&E and TFF3 protocols on a 




Acceptability of the Cytosponge® and subsequent endoscopy (regardless of 
sedation) was recorded using a visual analogue scale (VAS), wherein 10 indicated 
the best and 0 the worst experience. Patients in secondary care studies (BEST2, 
BEST-Australia, EoE Study, BEST2-RFA) underwent the Cytosponge® and 
endoscopy on the same day, whereas patients from BEST1 (primary care) had their 
endoscopy scheduled within three weeks and the acceptability score for endoscopy 
was not recorded. Number of swallow attempts and failure in swallowing the 
Cytosponge® were noted. ‘Failure to swallow’ was stated when the device could not 
be swallowed despite three attempts. Patients in BEST2 and EoE study had 
repeated Cytosponge® tests. All serious adverse events (SAE) were reported in 
accordance to the Good Clinical Practice guidelines. Minor events, such as sore 
throat, were not systematically recorded. 
Cytosponge ® abrasions grading system 
An abrasion grading system was introduced to categorize the severity of 
abrasions following the Cytosponge® procedure. The presence and degree of 
abrasions were recorded during subsequent EGD. Abrasions provide useful 
information on the most distal passage of the device (important for diagnosing BE) as 
well as a comparator with biopsies for the bleeding risk. The grading system is 
presented in Figure 2. 
Statistical Analysis 
Statistics for continuous variables were expressed as medians and 
interquartile ranges (IQRs). The Mann-Whitney test was used to compare continuous 
variables between groups. The association between failure in swallowing the 
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Cytosponge® and risk factors was analyzed using multivariable regression model. We 
reported odds ratios (OR) and 95% confidence intervals (CI) adjusted for patient’s 
sex, study setting, BMI and indication. All statistical tests were two-sided. For all 
analyses, P value of less than 0.05 was considered statistically significant. All 
analyses were performed using R Statistics version 3.4.3 (R Foundation for Statistical 
Computing, Vienna, Austria).  
RESULTS 
Patient Demographics 
In total, data on 2,418 patients from 5 studies between May 2008 and August 
2017 were analyzed. Eighty-four patients were unable to swallow the Cytosponge® 
(3.5%) and 50 were withdrawn due to study eligibility (2.1%), leaving 2,284 patients 
who successfully underwent the Cytosponge® test. The study cohort comprised of 
518 BEST1 patients (21.4%), 1,498 BEST2 patients (62.0%), 224 BEST-Australia 
patients (9.3%), 76 BEST2-RFA patients (3.1%), and 102 EoE study patients (4.2%).  
There were 1,329 patients with GERD (56.7%), 987 patients with previously 
diagnosed BE (40.8%; 911 from BEST2 and 76 from BEST2-RFA) and 102 patients 
with EoE (4.2%). The median age was 62 years (IQR 54-68) and the male to female 
ratio was 1.7:1.0. The median body mass index (BMI) was 28.2 kg/m2 (IQR 25.1-
31.5), indicating that most patients were overweight. The median waist-to-hip ratio for 
females was 0.86 (IQR 0.81-0.91) and for males it was 0.96 (IQR 0.92-0.99). 
Smoking status was recorded for 1,971 patients. Of these, 809 were reported as 
lifetime non-smokers (41.0%), 971 as former smokers (49.2%) and 191 as active 
smokers (9.7%). Majority of patients who underwent endoscopy had been diagnosed 
with hiatus hernia (53.7%). Combined demographic data is presented in Table 2.  
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Cytosponge ® Acceptability 
Overall, 2,672 Cytosponge® were performed, of which 2,289 had acceptability 
score recorded (85.7%). The endoscopy acceptability score was recorded for 1,406 
procedures in 1,221 patients. Of these, 1,175 endoscopies included data on sedation 
(96.2%), indicating that 402 EGD’s were performed without sedation (34.2%) and 773 
with sedation (65.8%).  
The overall acceptability for the Cytosponge® was satisfactory, with a median 
score of 6.0 (IQR 5.0-8.0). This was significantly higher when compared to 
endoscopy without sedation with median VAS score of 5.0 (IQR 3.0-7.0) (P<0.001), 
but still comparatively lower than endoscopy with sedation (VAS 8.0, IQR 5.0-
9.0)(P<0.001); see Figure 3. EoE patients had the highest acceptability for the test 
(VAS 8.0, IQR 5.1-9.0), as compared to patients with BE [VAS 7.0 (IQR 5.0-8.0)] and 
GERD [VAS 6.0 (IQR 4.9-8.0)]; P<0.001 for both comparisons. The presence of 
hiatus hernia did not influence the acceptability score (P=0.109). Males had higher 
acceptability than females [median 7.0 (IQR 5.0-8.0) vs 6.0 (IQR 5.0-8.0), P=0.003], 
as did patients in primary care setting, when compared to patients in secondary care 
(7.0 [IQR 5.0-8.0] vs. 6.0 [IQR 5.0-8.0], P<0.001). See Figure 4. 
Failure to swallow  the  Cytosponge ® 
Eighty-four patients failed to swallow the Cytosponge® (3.5%). The proportion 
of patients who were unable to swallow the device was over 2-times higher within BE 
patients than in GERD patients (5.7% vs 2.1%) and slightly higher within males as 
compared to females (3.9% vs 2.7%). All EoE patients successfully swallowed the 
device. The majority of successful tests were achieved with the first swallow attempt 
(90.1%). Using a multivariable regression model, we found that patients examined in 
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secondary care setting were over 5-times more likely to fail swallowing the device as 
compared to primary care setting (OR= 5.13, 95% CI 1.48-17.79, P<0.01). High BMI 
and gender were not associated with rates of failure in swallowing. Patients with 
previously diagnosed chronic diseases (BE and EoE combined) had a similar risk of 
swallow failure, when compared to patients with GERD. Supplementary table 1 
presents the multivariable regression model results.  
Cytosponge ® adverse events 
Overall, of the 2,672 Cytosponge® tests performed, there were 12 SAE 
reported, of which only 2 could be directly attributed to the Cytosponge® (<1: 2,000). 
These included one detachment of the sponge and one pharyngeal bleeding after 
Cytosponge® withdrawal. The others were related to endoscopic therapy performed 
immediately after the Cytosponge® test (see Supplementary table 2). As sore throat 
is a frequent event following endoscopy, we did not consider it an AE and the data 
was not collected systematically across all studies. No late AE, such as strictures 
have been reported. 
Cytosponge® detachment occurred in a 76-year-old male patient with BE in the 
BEST2-RFA study at the University of North Carolina. The patient did not report any 
discomfort when the device was retained. Since the Cytosponge® test was performed 
in the secondary care setting, it was retrieved endoscopically on the same day. The 
detached device was found in the pylorus and was successfully retrieved with a Roth 
net without further adverse consequences for the patient. 
There was one case of mild pharyngeal bleeding in a patient from BEST2 
study. The patient was on warfarin for atrial fibrillation, that was stopped prior to the 
procedure (INR was 1.2). The bleeding resolved spontaneously and there was no 
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drop in Haemoglobin levels. He was hospitalized as a precautionary measure and 
was discharged home the next day. 
Cytosponge ® abrasions 
A Cytosponge® abrasions grading system was devised in November 2011. It 
categorizes abrasions into five categories based on visual appearance of abrasions 
during endoscopy. This grading system was used in BEST2, BEST2-RFA and EoE 
Study. Overall, 1,075 Cytosponge® procedures were followed by an endoscopy with 
abrasion score assessment. In most of the cases (85.5%, 919/1075) Cytosponge® 
caused no or only mild abrasions (grade 0-2). There were only 24 cases (2.2%) of 
severe post- Cytosponge® abrasions (Grade 4) and no cases of grade 5 abrasions 
that required endoscopic or surgical intervention. Of note, Cytosponge® abrasions, 
even at the highest grade of 4, appear less severe when compared to current 
standard of care (quadrantic biopsies obtained every 2 cm - Seattle protocol27), as 
pictured in Figure 2.  
DISCUSSION 
 This technical review of five large prospective studies on the performance of 
the Cytosponge® showed that it is a safe procedure with good acceptability ratings. 
The test can be safely performed by a nurse in both the primary and secondary care 
setting, with minimal risk of AE. The Cytosponge® test was feasible when used for 
screening purposes (GERD patients with high-risk for BE), as well as for surveillance 
(EoE and BE after endoscopic treatment). 
Safety is paramount for any procedure especially when being performed in the 
primary care setting. Our review showed that of 2,672 Cytosponge® procedures there 
were only two SAE that could be directly attributed to the device (<1: 2,000) and both 
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resolved without any ill-effects for the patient. The detachment is the most concerning 
risk factor to both clinicians and patients28. However, a retained sponge in the 
stomach would not be expected to cause any symptoms as was the case in the 
patient reported here. Since objects greater than 2–2.5cm in diameter do not pass 
through the pylorus29, we expect the expanded sponge (which has a diameter of 3 
cm) to stay in the stomach after detachment and since endoscopy is widely available, 
retrievable should be easily arranged in case of this unlikely event.  
In a recent perspective article, it was reported that the Cytosponge® had been 
recalled due to two cases of detachment in the CASE1 study (FDA Recall Z-2123-
2016)30. We would like to emphasize that the above article refers to an alternative 
prototype device developed by Covidien GI Solutions (now Medtronic), not the 
original prototype patented by the Medical Research Council (MRC) UK, which was 
used in all the studies reported here. FDA and CE marking of the original device is 
underway [Cytosponge® received 510(k) clearance from the FDA on November 26, 
2014 (K142695)]. 
Previous interview-based, quality study on 33 participants with GERD showed 
that Cytosponge® is acceptable for most participants, as well as being preferred to 
endoscopy28. In our study, most patients (79.3%) scored their experience as at least 
“neutral” (VAS≥5) and the median VAS score was 6.0 (IQR 5.0-8.0). This was 
significantly higher when compared to endoscopy without sedation (VAS 5.0, IQR 
3.0-7.0), however lower than endoscopy with sedation (VAS 8.0, IQR 5.0-9.0, 
P<0.001 for both comparisons). It must be stressed, that the Cytosponge® has other 
advantages as a screening tool, when compared to the latter. Endoscopy with 
sedation is an invasive, time-consuming procedure (usually several hours including 
recovery time), that requires the patient to avoid work and operating machinery for 
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the subsequent 24 hours. Cytosponge® can be performed in 5-7 minutes, within a 
primary care office, and (usually) does not involve any restrictions for the remaining 
part of the day.  
Our review shows that patients with previously diagnosed chronic esophageal 
conditions (BE and EoE) have a higher acceptability rating for Cytosponge® as 
compared to patients with GERD (P<0.001). Supposably, these patients are more 
aware of the importance of undergoing regular monitoring and are more used to 
repeated endoscopic examinations, which might explain the higher degree of 
acceptability. Patients examined in the primary care setting (n= 518), had markedly 
higher acceptance, as compared to patients examined in the secondary care 
(n=2,154). The unequal size of the groups could be a confounding factor. 
Nevertheless, we postulate that the more patient-friendly environment and individual 
approach of a primary care setting benefits the overall acceptability of the test. These 
results are promising, since the Cytosponge® was developed to be a minimally 
invasive test for use in a primary-care offices.  
Prior to implementation in clinical practice, randomized trial data is required to 
fully evaluate the diagnostic yield of Cytosponge® and further evaluate its safety, 
acceptability and health economic outcomes. This is currently underway in the 
Barrett's ESophagus Trial 3 [(BEST3); trial ID ISRCTN68382401], a 10,000-patient 
cluster randomized controlled trial which is being conducted in multiple UK primary 
care surgeries (more information: https://www.best3trial.org/the-best3-trial, funded by 
Cancer Research UK). 
The main strength of the study is the direct access to original dataset to 
minimize missing data and ensure high quality of the statistical analyses. The studies 
were undertaken in several countries, for different indications and in different health 
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care settings. This study does have some limitations. There were comparatively 
fewer acceptability scores recorded for endoscopy than the Cytosponge®. This was 
because patients enrolled onto the BEST1 trial did not have the acceptability score 
recorded following endoscopy. Furthermore, the VAS scale is a crude measure of 
acceptability and further quantitative and qualitative interviews will be required to fully 
understand the patient experience. Some of the studies included in this analysis had 
more complex tools to measure patients’ experience, such as Impact Event Score or 
Spielberger state trait anxiety inventory, however we did not include it in this analysis 
since they were not used in all the studies. 
CONCLUSIONS 
 In conclusion, in this first review of clinical data on safety and acceptability of 
Cytosponge® we have demonstrated that this device has a favourable safety and 
acceptability profile. The relative ease of administration and the higher safety profile 
as compared to endoscopy makes it a promising tool to be used in the primary care 
setting as a screening and surveillance test for esophageal disorders such as BE or 
EoE. Results from the ongoing BEST3 randomized trial will be critical prior to 
implementing the Cytosponge® test for widespread use.  
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Table 1 . Characteristics of Cytosponge® studies included in the analysis 
Table 2. Demographic characteristics of patients from Cytosponge® studies.  Values 
are numbers (percentages) unless stated otherwise 
Figure 1  
A. Cytosponge® in gelatin capsule (right) and expanded (left).  
B, C. Haematoxylin and eosin (B) and trefoil-factor 3 (C) staining (20x) from patient 
with Barrett’s oesophagus showing columnar lined epithelium with goblet cells 
(arrowheads) (courtesy of dr Maria O’Donovan) 
D. Haematoxylin and eosin staining (200x) from patient with eosinophilic oesophagitis 
showing squamous epithelium with admixed eosinophils (arrowheads) 
Figure 2. The abrasion grading system after Cytosponge®  
Figure 3. Cytosponge® and endoscopy acceptability (per-procedure) 
Figure 4 . Acceptability scores for the Cytosponge® in different groups of patients 
(per-procedure). 
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Country: UK UK Australia USA USA 
Disease: GERD GERD and BE GERD BE after RFA 
treatment 
EoE 
No. of patients 
(%): 





518 (19.4%) 1,752 (65.6%) 224 (8.4%) 76 (2.8%) 102 (3.8%) 
Time of 
recruitment: 
May 2008 – Dec 
2009 
July 2011 – 
Dec 2013 



























• 18 – 80 
yrs. 
• BE with 




treatment   






















Up to 3 weeks Same day 
(within an 
hour) 
Same day Same day Same day (2 
hours prior to 
endoscopy) 
BE, Barrett’s esophagus; EoE, eosinophilic esophagitis; GERD, gastro-esophageal 
reflux disease; HGD, high-grade dysplasia; LGD, low-grade dysplasia; RFA, radio-
frequency ablation 
Table 2. Demographic characteristics of patients from Cytosponge® studies.  Values 
are numbers (percentages) unless stated otherwise 
Characteristics All participants* Men** Women** 
Age (years) - median (IQR) 62 (54-68) 63 (54-69) 61 (54-67) 
Missing data 153 (6.3) 119 (12.8) 36 (2.4) 
Number of participants 
All studies 2,418 (100) 1,486 (61.5) 932 (38.5) 
Study 1 (BEST1 Study) 518 (21.4) 240 (46.3) 278 (56.7) 
Study 2 (BEST2 Study) 1,498 (62.0) 1,035 (69.1) 463 (30.9) 
Study 3 (BEST Study Australia) 224 (9.3) 95 (42.4) 129 (57.6) 
Study 4 (POST-RFA Study) 76 (3.1) 58 (76.3) 18 (23.7) 
Study 5 (EoE Study) 102 (4.2) 58 (56.9) 44 (43.1) 
Indication to Cytosponge® 
GERD 1,329 (55.0) 632 (47.6) 697 (52.4) 
BE 987 (40.8) 796 (80.6) 191 (19.4) 
EoE 102 (4.2) 58 (56.9) 44 (43.1) 
Body Mass Index (BMI, kg/m2) 
Median (IQR) 28.2 (25.1-31.5) 28.1 (25.6-31.0) 28.6 (24.8-33.1) 
Underweight (<18.5) 14 (0.6) 12 (85.7) 2 (14.3) 
Normal (18.5 to 24.9) 447 (18.5) 185 (41.4) 262 (58.6) 
Overweight (25.0 to 29.9) 853 (35.3) 236 (27.7) 617 (72.3) 
Obese (≥30.0) 739 (30.6) 313 (42.4) 426 (57.6) 
Missing data 365 (15.0) 186 (51.0) 179 (49.0) 
Waist to Hip Ratio*** 
Median (IQR) 0.93 (0.87-0.98) 0.96 (0.92-0.99) 0.86 (0.81-0.91) 
Low Risk 786 (32.5) 622 (79.1) 164 (20.9) 
Moderate Risk 558 (23.1) 379 (67.9) 179 (32.1) 
High Risk 626 (25.9) 244 (39.0) 382 (61.0) 
Missing data 448 (18.5) 241 (53.8) 207 (46.2) 
Smoking Status 
Never 809 (33.5) 466 (57.6) 343 (42.4) 
Former 971 (40.2) 630 (64.9) 341 (35.1) 
Active 191 (7.9) 133 (69.6) 58 (30.4) 
Missing data 447 (18.5) 257 (57.5) 190 (42.5) 
Hiatus hernia 
Present 1,191 (49.3) 825 (69.3) 366 (30.7) 
Absent 1,025 (42.4) 538 (52.5) 487 (47.5) 
Missing data 202 (8.3) 123 (60.9) 79 (39.1) 
Previous endoscopic treatment (EMR, RFA, PDT) 
Yes 243 (10.0) 204 (84.0) 39 (16.0) 
No 2,175 (90.0) 1,282 (58.9) 893 (41.1) 
EMR, endoscopic mucosal resection; PDT, photo-dynamic therapy; RFA, radio-
frequency ablation;  
* The proportion (%) of patients from each group in the first column refers to the total
participant number 
** The proportion (%) of male and female patients refers to the number of participants
from each group (first row), not the total participant number 
*** Waist to hip ratio was considered low risk for male <0.95 and female <0.80, 






Supplementary Table 1. Multivariate analysis model for failure of swallowing the 
Cytosponge® 
* Since there were only 14 cases (0.6%) of underweight patients we did not include 
them in this analysis. 
BE, Barrett’s esophagus; CI, confidence interval; EoE, eosinophilic esophagitis; 
GERD, gastroesophageal reflux disease; OR, Odds ratio 
Factor OR 95% CI P value 
Gender 
Female (n=932) 1.00 - - 
Male (n=1,486) 1.08 0.61-1.90 P=0.79 
Study setting  
Primary care (n=518) 1.00 - - 
Secondary care (n=1,900) 5.13 1.48-17.79 P<0.01 
Body mass index* 
Normal BMI (n=447) 1.00 - - 
Overweight (n=854) 1.02 0.52-2.03 P=0.94 
Obese (n=739) 1.75 0.91-3.36 P=0.09 
Indication 
BE + EoE (n=987+102) 1.00 - - 
GERD (n=1,329) 0.63 0.35-1.14 P=0.13 
Supplementary Table 2. Combined adverse events from all studies included in the 
analysis 
Serious Adverse Events Study Number of 
events 
Cytosponge®adverse events 
Cytosponge®detachment from string 





Endoscopy adverse events 
Bleeding post-EMR and biopsy 
Chest pain post-EMR and syncope 
Post-RFA atrial fibrillation  
RFA-induced ulceration and bleeding 
Syncope 
Haematemesis from esophageal varices 
Epigastric pain  
Diarrhoea and coffee-ground vomiting post procedure 
Central chest pain and melena 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
1 
1 
1 
2 
1 
1 
1 
1 
1 
Total 12 
 
 
